Bariatric or metabolic surgery can significantly lower the risk of major cardiovascular events among patients with Type 2 diabetes and obesity, according to a new clinical study released at the European Society of Cardiology Congress in Paris. The retrospective study followed 13,722 Type 2 diabetes patients who underwent bariatric surgery to lose weight or metabolic […]
Senseonics touts BCBS reimbursement wins
Senseonics (NYSE:SENS) said today that Blue Cross Blue Shield of Massachusetts and Idaho now provide coverage for the implantable Eversense continuous glucose monitor. The company’s Eversense device includes a fluorescence-based sensor, a mobile app and a transmitter. Senseonics’ touts its system as being the first with a long-term, implantable CGM sensor, as well as the first […]
Insulet prices $700m offering
Insulet (NSDQ:PODD) today priced a private placement of $700 million in convertible senior notes due 2026. The offering is slated to close on Sept. 6. The Acton, Mass.-based company said in a press release it also gave initial purchasers an option to buy up to an additional $100 million in notes. Get the full story at our sister […]
Insulet announces $660m debt offering
Insulet (NSDQ:PODD) today announced a private offering of convertible senior notes worth $660 million. The notes are due in 2026 and the Acton, Mass.-based company is also offering initial purchasers an option to buy up to an additional $100 million aggregate principal amount of notes. Insulet said in a news release that it intends to use […]
Senseonics touts long-term safety data on home-use Eversense
Senseonics (NYSE:SENS) yesterday touted real-world data it said demonstrated the safety and lack of adverse events with its Eversense continuous glucose monitoring system for people with diabetes. Eversense is a long-term, implantable GCM sensor with a transmitter that sends discreet vibrations to alert users of low or high glucose. The device can be removed, recharged and […]
Nevro launches clinical trial of diabetic neuropathy treatment
Nevro (NYSE:NVRO) said today that it has completed patient enrollment in a clinical trial of its Senza HF10 therapy for patients with painful diabetic neuropathy. The Redwood City, Calif.-based company said the prospective, multicenter, randomized controlled trial compares its HF10 therapy plus conventional medical management to conventional treatment alone in 216 patients at 18 centers in […]
Dexcom claims win in patent war with AgaMatrix unit Waveform Technologies
Dexcom Inc. (NSDQ:DXCM) last week claimed a win along one front of its patent war with AgaMatrix subsidiary WaveForm Technologies, when an Oregon federal court dismissed a lawsuit alleging that its continuous glucose monitors infringe WaveForm patents. Wilsonville, Ore.-based WaveForm sued Dexcom in March 2016, alleging infringement of a trio of patents covering a compound […]
GI Dynamics announces $10m in financing
GI Dynamics (ASX:GID) announced yesterday that it agreed to terms of a financing of up to approximately $10 million with Crystal Amber (GBX:CRS) to continue developing its EndoBarrier device. EndoBarrier is a plastic sleeve designed treat Type 2 diabetes and obesity by preventing the absorption of nutrients from food as it exits the stomach and […]
These 5 DIY medical devices might surprise you
Big ideas in medical device development can come from regular people driven to solve vexing problems. Here are a handful of folks from outside the medtech industry who decided to create devices to solve their own health troubles or those of others around the world. Read on to see what high school, college and medical […]
Senseonics touts real-world CGM data
Senseonics (NYSE:SENS) announced yesterday that real-world data from its Eversense continuous glucose monitoring system reflected strong performance and safety. The data, published in Diabetes Technology and Therapeutics, included the first 205 U.S. patients to use Germantown, Md.-based Senseonics’ Eversense system over a 90-day wear period. Zero device or procedure-related adverse events were reported with the […]
Baxter foundation, Direct Relief ink diabetes pact
Baxter (NYSE:BAX) and Direct Relief announced today that they are launching a three-year program awarding funding to health centers and free and charitable clinics that are working to improve diabetes outcomes for patients. The program, Transformative Innovation Awards for Community Health: Incorporating Nutrition to Improve Diabetes Health Outcomes, will award $750,000 to the centers and clinics, […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 84
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube